Analyst Downgraded Stocks on the NAS June 2024

June 27, 2024

Analyst Downgrades

Companies are downgraded when at least one analyst has downgraded their view on the stock, therefore decreasing its average consensus value. Companies can get downgraded for a number of reasons but primarily due to reduced future earnings potential due to loss of contracts, faltering product lines, increasing costs relative to revenue or financial risk.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

About the Data

This table includes the number of analyst ratings along with the number of buy-hold-sells on the company. A company is included in this list when its mean rating decreases from the previous week.

How do you use this table?

Companies that have recently been downgraded are viewed as having potential future losses. Use this table as a starting point for further research on these companies. Stocks with analyst coverage also tend to have higher visibility in the marketplace, therefore have the potential to be more liquid. Stocks in this category are generally sold to preserve capital or held as a short position.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameBuyOutperformHoldUnderperformSellNo OpinionMean RatingPrev Mean LabelMean Label
LQDA Liquidia Corp 1 0 1 0 0 0 4.0 5.0 Outperform
ALIM Alimera Sciences Inc 2 0 1 0 0 0 4.3 5.0 Outperform
All data provided as at market close June 24, 2024.

Company Details

Liquidia Corp

LQDA:NAS

Buy

1

Hold

1

Mean Rating

4.0

Prev Mean Rating

5.0

Mean Label

Outperform

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease.

Access the stockcalc valuation


Alimera Sciences Inc

ALIM:NAS

Buy

2

Hold

1

Mean Rating

4.3

Prev Mean Rating

5.0

Mean Label

Outperform

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S.

Access the stockcalc valuation


Analysts downgraded Liquidia and Alimera Sciences on the NAS this month. See the full list of analyst downgrades on the blog: https://www.stockcalc.com/Blog/analyst-downgraded-stocks-nas-june-2024
Liquidia $LQDA and Alimera Sciences $ALIM downgraded on the #NAS this month. See the full list of downgrades: https://www.stockcalc.com/Blog/analyst-downgraded-stocks-nas-june-2024
Analysts downgraded Liquidia and Alimera Sciences on the NAS this month. See the full list of analyst downgrades on the blog: https://www.stockcalc.com/Blog/analyst-downgraded-stocks-nas-june-2024

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.